PER2 and breast carcinoma: In addition, clinical studies have shown that Per2 expression is reduced in cancer patients, and it plays a tumour suppressor role in breast cancer, skin tumours, hepatocellular carcinoma, colorectal cancer and head and neck squamous cell carcinoma15, 16, 17, 18, 19.